Table 2. Anti-VGEF Agents Which Are Currently in Clinical and Pre-clinical Stages^a.

drug/protein name	molecular weight (kDa)	half-life	description	target	phase	company	current indication	clinical trails.gov identifier
Ranibizumab [Lucentis]	48.35	9 days	recombinant humanized IgG1 kappa isotype monoclonal antibody	VEGF-CC1	FDA approved	Genentech	DME, DR, AM
Pegaptanib Sodium [Macugen]	50	10 ± 4 days	polynucleotide aptamer	VEGF-165	FDA approved	Gilead sciences	wet AMD
Ocriplamin [Jetrea]	27.2	N.A.	recombinant human plasmin	fibronectin, Alpha-2 macroglobulin	FDA Approved	Thrombogenic NV	VMA, VRI
				Alpha-2 Antiplasmin
Aflibercept [Eylea]	115	7.13 days	recombinant fusion protein glycosylated	VEGF-A, B, and placenta growth factor	FDA Approved	Regeneron	DR, DME, AMD, CRC
						Bayer
Brolucizumab [Beovu]	26	4.4 ± 2 days	proteins-based monoclonal antibody	VEGF-A	FDA Approved	Novartis	nAMD
Vgx-300 [opt 302]	N.A.	N.A.	recombinant fusion protein	VEGF - C, D	Phase- 3 [Recruiting]	Opthea limited	nAMD	NCT04757610
Rn6g	N.A.	N.A.	antiamyloid beta antibody	amyloid beta fibrils in drusen	Phase-2 [Terminated]	Pfizer	AMD, GA	NCT01577381
Conbercept [Lumitin]	143	4.2 days [In rabbit]	recombinant fusion protein	VEGF-A/B placenta growth factor	Phase-3 [Rejected]	Chengdu kanghong Biotech	AMD	NCT03577899
Lampalizumab	47	6 days	fragment of humanized monoclonal antibody	CFD	Phase-3 [Rejected]	Roche	GA, AMD	NCT02247479
Bevacizumab [Avastin]	149	estimated 20 days	humanized monoclonal IgG Antibody	VEGF-A	off label	Roche, Genentech	Wet AMD, Cancer

^aVMA, Vitreomacular adhesion; GA, geographic atrophy; AMD, age-related macular degeneration; DR, diabetic retinopathy; VRI, vitreoretinal interface; nAMD, neovascular age-related macular degeneration; DME, diabetic macular edema; and CRVO, macular edema with central retinal vein occlusion.